What prospects for leading regions and countries?Developments worldwide will influence the market from 2013. There are many opportunities for healthcare companies large and small. You discover individual revenue forecasts to 2023 for eight national markets and two regional blocks. Find relevant overall sales:• US• Canada• Japan• Germany, France, UK, Italy and Spain (EU5 countries)• Europe• Brazil, Russia, India and China (BRIC nations, grouped analysis). You find potential. High sales growth will occur in established pharma markets and in developing countries, our analyses show. In particular, drug launches will change the commercial landscape to 2023. Research and development - see trends and possibilities What's happening in epigenetic R&D? You see trends and outlooks there: • HDAC inhibitors • DNMT inhibitors • Treatments targeting other enzymes • MiRNA therapy • Diagnostics pipeline. Our study also discusses these technologies, among others:• New drug targets• Biomarkers• Bioinformatics• Next generation sequencing. Discover progress. You assess innovations affecting the industry's future - hear about developments and find their significance. Our work explains, exploring many issues. What affects the application of epigenetics? Our report discusses issues and events affecting that science, industry and market from 2013 onwards: • Cancer research and treatment • DNA hypomethylation in autoimmune diseases • Neurodegenerative diseases • Neurological disorders • Understanding of epigenetic markers and mechanisms. Also, you find coverage of these aspects of the field:• Genomics, proteomics and metabolomics• Translational research• Licensing, outsourcing and academic collaborations• Developments with stem cells• Orphan indications and patient subpopulations• Companion diagnostics and stratified medicine. See what the future holds. You investigate technological, commercial, economic and political matters, with emphasis on companies, competition and business outlooks.